Disseminated Intravascular Coagulation (DIC): Systemic Coagulation Failure
Disseminated intravascular coagulation (DIC) is a pathological process characterised by widespread activation of the coagulation system throughout the circulation. Rather than forming clots where they are needed, coagulation becomes systemic and uncontrolled. This leads simultaneously to microvascular thrombosis and depletion of clotting factors, resulting in bleeding. DIC is not a primary disease but a complication of severe underlying pathology. Understanding its pathophysiology explains why patients can clot and bleed at the same time.
What You Need to Know
Disseminated intravascular coagulation is a systemic failure of haemostatic regulation, not a primary bleeding disorder. It develops when coagulation pathways are activated across the circulation rather than at a local site of injury. Widespread activation of clotting leads to the formation of fibrin-rich microthrombi within small vessels, impairing capillary blood flow and contributing to tissue hypoxia and organ dysfunction. At the same time, platelets and clotting factors are progressively consumed, reducing the body’s ability to form stable clots where they are actually needed.
DIC is characterised by the simultaneous presence of thrombosis and bleeding, driven by uncontrolled coagulation rather than loss of clotting capacity alone. Endothelial injury, inflammatory mediators, and tissue factor release amplify thrombin generation. Natural anticoagulant systems, such as antithrombin and the protein C pathway, become overwhelmed or depleted, while fibrinolysis may be either excessive or suppressed. This loss of balance prevents normal containment and resolution of clot formation.
DIC most commonly develops in the setting of severe systemic illness, including:
sepsis and severe infection
major trauma or extensive tissue injury
obstetric complications such as placental abruption or amniotic fluid embolism
malignancy, particularly haematological and mucin-producing tumours
In each case, the trigger initiates widespread coagulation rather than a controlled local response.
As microthrombi accumulate, perfusion at the microcirculatory level becomes increasingly impaired. Organs with high metabolic demand, such as the kidneys, lungs, brain, and liver, are particularly vulnerable. Bleeding occurs because platelets and clotting factors have been consumed faster than they can be replaced, not because coagulation is inactive. The clinical presentation therefore varies, ranging from subtle laboratory abnormalities to fulminant bleeding and multiorgan failure, depending on the speed and severity of the underlying process.
Beyond the Basics
Triggering Events and Tissue Factor Release
Disseminated intravascular coagulation begins when coagulation is activated on a scale that overwhelms normal regulatory control. Tissue factor is the key initiator. It is released not only from damaged endothelium but also from activated monocytes, macrophages, and injured tissues during severe inflammation, trauma, or obstetric events. Once tissue factor enters the circulation, it activates the extrinsic coagulation pathway, leading to rapid and widespread thrombin generation.
In normal haemostasis, thrombin generation is localised and short-lived. In DIC, thrombin production becomes systemic and sustained. This shifts coagulation from a protective mechanism into a pathological process, driving clot formation throughout the microvasculature rather than at a single injury site.
Microvascular Thrombosis and Impaired Perfusion
Excess thrombin converts fibrinogen into fibrin, leading to deposition of fibrin strands within small vessels. These microthrombi obstruct capillary blood flow and disrupt normal microcirculatory exchange. Even when large-vessel blood flow appears adequate, capillary obstruction prevents effective oxygen and nutrient delivery at the tissue level.
Organs with extensive microvascular networks are particularly susceptible. In the kidneys, reduced capillary perfusion impairs filtration and leads to acute kidney injury. In the lungs, microthrombi worsen ventilation–perfusion mismatch and contribute to hypoxaemia. In the brain, reduced microvascular flow can result in altered consciousness or ischaemic injury. Organ dysfunction in DIC is therefore driven by microcirculatory failure rather than large-vessel occlusion.
Consumption of Platelets and Clotting Factors
As coagulation continues unchecked, platelets and clotting factors are consumed faster than they can be replaced. This creates a consumptive coagulopathy. Platelet counts fall, fibrinogen levels drop, and clotting times become prolonged. The liver and bone marrow are unable to compensate at the rate required, particularly in the setting of shock or liver dysfunction.
Bleeding in DIC occurs despite ongoing clot formation. This apparent paradox arises because the components required for effective haemostasis have been exhausted. Bleeding may occur from venepuncture sites, surgical wounds, mucosal surfaces, or internally, even while microthrombi continue to impair organ perfusion.
Failure of Anticoagulant Pathways
Physiological anticoagulant systems normally act as brakes on coagulation. Antithrombin neutralises thrombin, while the protein C system limits further clot propagation. In DIC, these systems are depleted, consumed, or functionally impaired. Inflammatory cytokines downregulate endothelial anticoagulant activity, and endothelial injury removes critical regulatory surfaces.
Loss of anticoagulant control allows thrombin generation to continue unchecked. This shifts the balance entirely toward clot formation, amplifying microvascular thrombosis and worsening organ injury. The failure of these pathways explains why DIC cannot self-limit once established.
Fibrinolysis and Bleeding Risk
Fibrinolysis, the system responsible for breaking down fibrin clots, becomes dysregulated in DIC. In some cases, fibrinolysis is excessively activated, leading to rapid clot breakdown and worsening bleeding. In other cases—particularly in sepsis—fibrinolysis is suppressed, allowing microthrombi to persist and accumulate within the circulation.
This imbalance means that DIC may present with predominant bleeding, predominant thrombosis, or a combination of both. The clinical picture depends on how coagulation and fibrinolysis are altered in response to the underlying trigger. Regardless of the pattern, disruption of fibrinolytic control further contributes to circulatory failure and organ dysfunction.
Clinical Connections
Disseminated intravascular coagulation rarely presents as an isolated coagulation disorder. It typically emerges in the context of severe systemic illness, most commonly sepsis, shock, major trauma, or obstetric catastrophe. Clinical deterioration often reflects progression of the underlying condition rather than DIC itself, making early recognition challenging.
Patients may show simultaneous bleeding and thrombosis, a defining feature that distinguishes DIC from primary bleeding disorders or isolated thrombotic disease. Bleeding is often diffuse and persistent, while thrombosis manifests as organ dysfunction rather than visible clots.
Common clinical features include:
oozing from venepuncture sites, surgical wounds, or mucosal surfaces
petechiae, ecchymoses, or purpura due to platelet consumption
signs of organ hypoperfusion such as reduced urine output, altered mental status, or respiratory compromise
unexplained thrombotic events, particularly in the microcirculation
Laboratory abnormalities reflect consumptive coagulopathy rather than simple anticoagulation. Typical findings include thrombocytopenia, prolonged PT and aPTT, low fibrinogen, and elevated fibrin degradation products or D-dimer. Importantly, no single laboratory value confirms or excludes DIC. Diagnosis relies on recognising a pattern of evolving abnormalities in the appropriate clinical context.
DIC often progresses in parallel with shock and systemic inflammation. Worsening lactate, escalating vasopressor requirements, or new organ dysfunction frequently coincide with deteriorating coagulation parameters. This reflects shared underlying mechanisms, endothelial injury, inflammatory amplification, and microcirculatory failure.
Management is directed at interrupting the driving pathology, not simply correcting laboratory values. Treating sepsis, controlling haemorrhage, resolving hypoxia, or delivering the fetus in obstetric DIC are central to recovery. Supportive measures such as blood product replacement are adjunctive and guided by bleeding risk and clinical instability rather than numbers alone.
Concept Check
Why is DIC considered a consumptive coagulopathy?
How do microthrombi contribute to organ dysfunction in DIC?
Why can patients with DIC bleed despite widespread clot formation?
How does endothelial injury amplify coagulation in DIC?
Why is treating the underlying cause essential in DIC management?